Modern 5-HT receptor classification and 5-HT based drugs

References

• GADDUM JH, PICARELLI ZP: Two kinds of tryptamine receptors. Br J. Pharmacol. (1957) 12:323–328.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, FERRARI MD: From serotonin receptor clas-sification to the antimigraine drug sumatriptan., Cepha-lalgia (1992) 12:187–196
   PubMed Web of Science ®Google Scholar
• PEROUTKA SJ, SNYDER SH: Multiple serotonin receptors: differential binding of PHI-5-hydroxytryptamine, lysergic add diethylamide and (311)-spfroperidoL Mol. Pharmacol.. (1979) 16:687–699.
   Web of Science ®Google Scholar
• HUMPHREY PPA: Pharmacological characterization of cardiovascular 5-hydroxytryptamine receptors. In: Vas-cular NeuroeffectorMechanism, Fourth International Sympo-sium, Bevan JA, Fujiwara M, Maxwell RA, Mohri K, Shibata S, Toda N (Eds) Macmillan Press, London. 1983, 237–243.
   Google Scholar
• VERDOUW PD, JENNEWEIN HM, HEILIGERS JPC,DUNCKER DJ, SAXENA PR: Redistribution of carotid artery blood flow by 5-hydroxytryptamine: Effect of the 5-11T2 receptor antagonists ketanserin and WAL 1307. Eur. J. Pharmacol. (1984) 102:499–509.
   PubMed Web of Science ®Google Scholar
• BRADLEY PB, ENGEL G, FENIUK W, FOZARD JR, HUM-PHREY PPA, MIDDLEMISS DN, MYLECHARANE EJ, RICHARDSON BP, SAXENA PR: Proposals for the classifi-cation and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 25:563–576.
   PubMed Web of Science ®Google Scholar
• DUNCKER DJ, SAXENA PR, VERDOUW PD: 5-Hy-droxytryptamine causes tachycardia in pigs by acting on receptors unrelated to 5-HT1, 5-HT2 or M-type. Br J. Pharmacol. (1985) 86:596F.
   Google Scholar
• KILPATRICK GJ, JONES BJ, TYERS MB: The identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature (1987) 330:746–748.
   PubMed Web of Science ®Google Scholar
• SAXENA PR: Nature of the 5-hydroxytryptamine recep-tors in mammalian heart. Progr. Pharmacol. 1986, 6173–185.
   Google Scholar
• BOM All, DUNCKER DJ, SAXENA PR, VERDOUW PD: 5-hy-drox-ytryptamine-induced tachycardia in the pilp pos-sible involvement of a new type of 5-hydroxytryptamine receptor. Br J. Pharmacol. (1988) 93:663–671.
   PubMed Web of Science ®Google Scholar
• DUMUIS A, BOUHELAL R, SEBBEN M, BOCKAERT J: A 5-HT receptor in the central nervous system positively cou-pled with adenyl cyclase is antagonized by ICS 205-930. Eur. J. Pharmacol. (1988) 146:187–188.
   PubMed Web of Science ®Google Scholar
• DUMUIS A, SEBBEN M, BOCKAERT J: The gastrointestinal prokinetic benramide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn-Scbmiedebergs Arch. Pharmacol. (1989) 340:403–410.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, HARTIG P, HOYER D: A proposed newnomenclature for 5-HT receptors. Trends Pharmacol. Sci. (1993) 14:233–236.
   PubMed Web of Science ®Google Scholar
• HOYER D, CLARKE DE, FOZARD JR, HARTIG PR, MARTINGR, MYLECHARANE EJ, SAXENA PR, HUMPHREY PPA: The IUPHAR classification of receptors for 5-hydroxytryp-tamine (serotonin). Pharmacy!. Rev. (1994) In press.
   Google Scholar
• KENAIUN TP, BOND RA, BONNER TI: Definition of phar-macologicalreceptors. Pharmacol. Rev. (1992)44:351–362.
   PubMedGoogle Scholar
• SAXENA PR, VILLALON CM: Cardiovascular effects of serotonin agonists and antagonists. J. Cardiovasc Phar-macol. (1990) 15(Suppl 7):S17–S34.
   PubMedGoogle Scholar
• PLASSAT JL, AMLAIKY N, HEN R: Molecular cloning of a mammalian serotonin receptor that activates adenylyl cyclase. Mol Pbarm (1993) 44:229–236.
   PubMed Web of Science ®Google Scholar
• FLETCHER A, BILL DJ, BILL SJ, CLIFFE IA, DOVER GM, FORSTER EA, HASKINS JT, JONES D, MANSELL HE, REILLY Y: WAY100135: a novel, selective antagonist at presy-naptic and postsynaptic 5-HTtA receptors. Eur. J. Phar-macol. (1993) 237:283–291.
   PubMed Web of Science ®Google Scholar
• SKINGLE M, SCOPES DIC, FENIUK W, CONNOR HE, CAR-TER MC, CLITHEROW JW, TYERS MB: GR127935: a potent orally active 5-HTan receptor antagonist. Br. J. Pharma-col. (1993) 110:9P.
   Web of Science ®Google Scholar
• SONG F, FREEMANTLE N, SHELDON TA, HOUSE A, WAT-SON P, LONG A, MASON 3: Selective serotonin reuptake Inhibitors: meta-analysis of efficacy and acceptability. BMJ (1993) 306: 683–687.
   PubMed Web of Science ®Google Scholar
• STOKES PE: Fluoxetirte: a five-year review. Clin.-Ther.(1993) 15: 216–243.
   PubMedGoogle Scholar
• ANGEL I, SCHOEMA10ER H, PROUTEAU M, GARREAU M, LANGER SZ: Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antic-metic properties. Eur. J. Pharmacol. (1993) 232:139–145.
   PubMed Web of Science ®Google Scholar
• GOLDBERG HL, FINNERTY RJ: The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiat (1979) 136:1184–1187.
   PubMed Web of Science ®Google Scholar
• GOA KL, WARD A: Buspirone, a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs (1986) 32:114–129.
   PubMed Web of Science ®Google Scholar
• GLASSER T: Ipsapirone, a potent and selective 5-HT1a receptor ligand with anxiolytic and antidepressant properties. Drugs Fut. (1988) 13:429–439.
   Google Scholar
• COSTELLO NL, CARLSON JN, GLICK SD, BRYDA M: The effects of acute administration of gepirone in rats trained on conflict schedules having different degrees of predictability. Pharmacol. Biochem. Bebav. (1991) 40:795–800.
   PubMed Web of Science ®Google Scholar
• PECKNOLD JC, LUTHE L, SCOTT FLEURY MH, JENKINS S: Gepirone and the treatment of panic disorder: an open study. J. Clin. Psychopbarmacol. (1993) 13:145–149.
   PubMed Web of Science ®Google Scholar
• RAMAGE AG: A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetized cats. Eur. J. Pharmacol. (1986) 129:307–314.
   PubMed Web of Science ®Google Scholar
• KOLASSA N, BETTER 1(D, BOER R, BOSS H, SANDERS ICH:Urapidil: the role of 5-HTIA and a-adrenergic receptors In blood pressure reduction. In: Serotonin, Cell Biology to Pharmacology and Therapeutics, Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (Eds) Kluwer Academic Publishers, Dordrecht. 1992, 151–157.
   Google Scholar
• SAXENA PR, VILLADON CM: Brain 5-HT1i. receptor agonism: a novel mechanism for antihypertensive ac-tion. Trends Pbarmacol. Sci. (1990b) 11:95–96.
   Google Scholar
• FERRARI MD, SAXENA PR: Clinical and experimental effects of sumatriptan in humans. T'rends Pharmacyl. Sci. (1993) 14:129–133.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, TFELT-HANSEN P: Swmatriptan. In: The Head-aches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Raven Press, New York. 1993, 329–341.
   Google Scholar
• WELCH KMA: Drug therapy of migraine. N. Engl. J. Med. (1993) 329:1476–1483.
   PubMed Web of Science ®Google Scholar
• CONNOR H, O'SHAUGHNESSY CT, FENIUK W, PERREN MJ, CONNOR H, O'SHAUGHNESSY CT, FENIUK W, PERREN MJ,
   Google Scholar
• PERREN MJ, CONNOR H, FENIUK W, NORTH PC, SAYNORDA, HUMPHREY PPA: Pharmacological activity in vivo of GR85548, a selective 5-HT1 receptor agonist Br. J. Phar-macol. (1993) 108:260P.
   Web of Science ®Google Scholar
• ROBERTSON AD, HILL AP, GLEN RC, MARTIN GR: Thera-peutic heterocyclic compounds. Wellcome Foundation Patent No W09118897
   Google Scholar
• MCGOURTY JC, SILAS JH, COWAN 1(3: Controlled trial ofketanserin in hypertension. Br. J. Clin. Pharmacol. (1985) 20:37-40. NORTH PC, OXFORD AW, BUTINA D, OWEN M, HUM-PHREY PPA: GR85548, a potent selective agonist for the intracranial vascular 5-HT1 receptor. Br. J. Pharmacol. (1993) 108:99P.
   Google Scholar
• SAXENA PR, WOUTERS W: Interferences with 5-hy-droxytryptamine. In: Pharmacology of antihypertensive therapeutics, Handbook of Pharmacology, vol 93, Ganten D, Mulrow PJ (Eds) Springer Verlag, Heidelberg. (1990) 533–558.
   Google Scholar
• WESTERBERG HGM, DEN BOER JA: Serotonin-influenc-ing drugs in the treatment of panic disorders. Psychopa-thology (1989) 22(Suppl 1):68–77.
   PubMedGoogle Scholar
• CASTELAO JR, FERREIRA L, GELDERS YJ, HEYLEN SLE: The efficacy of the D-2 and 5-HT2 antagonist risperidone (R 64766) in psychotic patients. Schizophrenia Res. (1989) 2:411–415.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, DEN BOER MO: Pharmacology of anthill-graine drugs. J. Neurol. (1991) 238(Suppl 1):S28–S35.
   PubMedGoogle Scholar
• TFELT-HANSEN P, SAXENA PR: Antiserotonin drugs. In: The Headaches. Olesen J, Tfek-Hansen P, Welch KMA (Eds) Raven Press, Ltd, New York. 1993, 373–382.
   Google Scholar
• ICENNETT GA: 5-HTic receptors and their therapeuticrelevance. Current Drugs: Serotonin 1993, April issue:125-170.
   Google Scholar
• FOZARD JR: 5-HTic receptor agonism as an initiatingevent in migraine. In: 5-Hydroxytryptamine mechanisms in primary headaches. Olesen J, Saxena PR (Eds) Raven Press, New York. 1990, 200–212.
   Google Scholar
• FOZARD JR, GRAY JA: 5-HTic receptor activation: a key step in the initiation of migraine. Trends Pharmacol. Sci. (1989), 10:307–309.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM, GROSHEN S, ROBINSON DC, STEVENSON LL, SANDERSON PE: Correlation of anti-emetic efficacy and plasma levels of ondansetron. Eur. J. Cancer (1990) 26:879–882.
   PubMed Web of Science ®Google Scholar
• MARTY M, POULLLART P, SCHOOL S, DROZ JP, AZAB M,BRION N, PUJADE-LAURAINE E, PAULE B, PAES D, BONS J: Comparison of the 5-hydroxytryptamine3 (sero-tonin) antagonist ondansetron (GR 380320 with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl.J. Med. (1990) 322:816–821.
   PubMed Web of Science ®Google Scholar
• CHEVALLIER B (on behalf of the granisetron study group): Efficacy and safety of granisetron compared to high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin. Eur. I Cancer (1990) 26(Suppl 1):33–36.
   PubMedGoogle Scholar
• DOGLIOTTI L, FAGGINOLO R, BERRUT A, ANTOMACCI RA, ORTEGA C, LANCRANJAN J: Prevention of nausea and vomiting in cisplatin-treated patients by a selective (5 HT3) receptor antagonist, ICS 205-930. Tumork (1990) 76:595–598.
   PubMed Web of Science ®Google Scholar
• COSTALL B, DOMENEY AM, KELLY ME, NAYLOR RJ: Newantidementia molecules which selectively influence serotonin receptor subtypes. In: Serotonin, Cell Biology to Pharmacology and Therapeutics, Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (Eds) Kluwer Academic Publishers, Dordrecht. 1993, 407–416.
   Google Scholar
• FERRARI MD: 5-HT3 receptor antagonists and migraine therapy. J. Neurol (1991) 238(Suppl 1):S53–S56.
   PubMedGoogle Scholar
• FERRARI MD, WILKINSON M, HIRT D, LATASTE X, NOIIER M: Efficacy of ICS 205-930, a novel 5-hydroxytryp-tarnine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question. ICS 205-930 Migraine Study Group. Pain (1991) 45:283–291.
   Google Scholar
• HAGAN RM, KILPATRICK GJ, TYERS M: Interactions be-tween 5-HT3 receptors and cerebral dopamine func-tion: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (1993) 112(Suppl 1):S68–S75.
   PubMed Web of Science ®Google Scholar
• PRESTON GC, MILLSON DS, CEUPPENS PR, 'WARBURTON DM: Effects of the 5-HT3 receptor antagonist GR-68755 on a scopolamine-induced cognitive deficit in healthy subjects. Br. J. Clin. Pharmacol. (1992) 33:546.
   Google Scholar
• BRIEJER MR, AKKERMANS LM, MEULEMANS AL, LEFEBVRE RA, SCHUURKES JA: Cisaprkie and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn-Scbmiedebergs Arch Pharmacol. (1993) 347:464–470.
   PubMedGoogle Scholar
• KING FD, HADLEY MS, JOINER KT, MARTIN RT, SANGER GJ, SMITH DM, SMITH GE, SMITH P, TURNER DH, WATTS EA: Substituted benT2miries with conformationally re-stricted side chains. 5. Azabicycksfx.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants. J. Med. Chem. (1993) 36:683–689.
   Google Scholar
• GULLIKSON GW, VIRINA MA, LOEFFLER RE, YANG DC, GOLDSTIN B, WANG SX, MOUMMI C, FLYNN DL, ZABROWSKI DL: SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism. j Pharmacol. Exp. Ther. (1993) 264:240–248.
   PubMed Web of Science ®Google Scholar
• OXFORD AW: Substituted phenylcarbamates and phenylureas, their preparation and use as 5-UT antago-nists. Glaxo Group Limited Patent No W09320071.
   Google Scholar
• KAUMANN AJ, SANDERS L: 5-Hydroxylryptamine causes arrhythmias in isolated human atrium. Br.J. Pharmacol. (1993) 108:245P.
   Web of Science ®Google Scholar
• CHARNEY DS, 'CRYSTAL JH, DELGADO PL, HENINGER GR:Serotonin-specific drugs for anxiety and depressive disorders. Ann. Rev. Med. (1990) 41:437–446.
   PubMed Web of Science ®Google Scholar
• MURPHY DL, BROOCKS A, AULAKH C, PIGOTT TA: Anx-iolytic effects of drugs acting on 5-HT receptor subtypes. In: Serotonin, Cell Biology to Pharmacology and Therapeutics, Vanhoutte PM, Saxena PR, Paoletti R, Brunelle) N, Jackson AS (Eds) Kluwer Academic Publishers, Dordrecht. 1993,223–230.
   Google Scholar
• GREENSHAW AJ: Behavioral pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potentiaL Trends Pharmacol. Sci. (1993) 14:265–270.
   Google Scholar
• SMITH DW, YOCCA FD, YEVICH JP, MATTSON RJ: Antimi-graine alkoxypyrimidine derivatives. Bristol-Myers Squibb Co Patent No FP-464558, 1992.
   Google Scholar
• JOHNSON MR, NORTH PC: Indole derivatives. Glaxo Group Ltd, Patent No 1V09314087, 1993.
   Google Scholar
• BAKER R, MATASSA VG, REEVE AJ: 4-Substituted 1,2,4-triazole derivatives. Merck Sharp & Dohme Ltd Patent No EP-581538, 1994.
   Google Scholar
• MCDONALD IA, DUDLEY MW, BERNOTAS RC, SPROUSE JS: Serotonin 5-HT1A and 5-HTto antagonists. Merrel Dow Pharmaceuticals Inc Patent No EP-478954, 1992.
   Google Scholar
• KING FD, GASTER LM, KAUMANN AJ, YOUNG RC: Use of tetrahydrocarbazone derivatives as 5-HT' receptor agonists. SmithKline Beecham plc, Patent No W09300086, 1993.
   Google Scholar
• WINTHER K: Ketanserin, a selective serotonin receptorantagonist, in relation to platelet aggregation and mi-graine attack rate. Cephalalgia (1985) 5(Suppl 3):402–403.
   Google Scholar
• DAVIES PTG, STEINER TJ: Serotonln Sz receptors and migraine: a study with the selective receptor antagonist ICI 169,369. Headache (1990) 30:340–343.
   PubMed Web of Science ®Google Scholar
• BROWN AM, PATCH TL, KAUMANN AJ: The antitnigraine drugs ergotamine and dihydroergotamine are potent 5-HTic receptor agonists in piglet choroid plexus. Br. J.. Pharmacol.. (1991) 104: 4548.
   Google Scholar
• LOISY C, BEORCHIA S, CENTZONE V, FOZARD JR, SCHECHTER PJ, TELL GP: Effects on migraine headache of MDL 7222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study. Cephalalgia (1985) 5:79–82.
   Google Scholar
• COUTURIER EG, HERING R, FOSTER CA, STEINER TJ, CLIFFORD ROSE F: First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache (1991) 31:296–297.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, BAX WA, FERRARI MD: 5-Hydroxytryp-ta.mine receptor subtypes and antimigraine action. Ind. Pharmacol. (1993) 25:60–67.
   Google Scholar
• FOZARD JR: Agonists and antagonists of 5-HT3 recep-tors. In: Cardiovascular Pharmacology of 5-hydrazytryp-tamine: Prospective Therapeutic Applications, Saxena PR, Wallis DI, Wouters W, Bevan P (Eds) Kluwer academic publishers, Dordrecht. 1990, 101–115.
   Google Scholar
• GRALLA RJ, HARI LM, PISKO SE, SQUILLANTE AE, ICELSON DP, BRAUN DW, BORDIN IA, BRAUN II, YOUNG CW: Antiemetic efficacy of high dose metoclopramide: ran-domized trial with placebo and prochlorperazine in patients with chemotherapy induced nausea and vom-iting. N. Engl. J. Med. (1981) 305:905–909.
   PubMed Web of Science ®Google Scholar
• MINER WD, SANGER CJ: Inhibition of cisplatin-Induced vomiting by 5-hydroxytryptamine M-receptor antago-nism. Br.j Pharmacol. (1986) 88:497–499.
   PubMed Web of Science ®Google Scholar
• WELLS U, RA'VENSCROFT M, BHANDARI P, ANDREWS PLR: Serotonin and serotonergic drugs in emesis.Sero-tonin, Cell Biology to Pharmacology and Therapeutics, Van-houtte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (Eds) Kluwer Academic Publishers, Dordrecht. 1993, 179–186.
   Google Scholar
• DHASMANA KM, ZHU YN, CRUZ SL, VILLALÓN CM: Gas-trointestinal effects of 5-hydroxytryptamine and re-lated drugs. Life Sci. (1993) 53:1651–1661.
   PubMed Web of Science ®Google Scholar
• PRIOR A, READ NW: Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3seceptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1993) 7:175–180.
   PubMed Web of Science ®Google Scholar
• GORES, GILMORE IT, HAIGH CG, BROWNLESS SM, STOCK-DALE H, MORRIS Al: Colonic transit in man is slowed by ondansetron (GR 38032F), a selective 5-hydroxytryp-tamine receptor (type 3) antagonist. Aliment Pharmacol. Ther (1990) 4:139–144.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, PHILIPS SF, HADDAD A, MILLER LJ, TWOMEY C, ZINSMEISTER AR, MACCARTY RL, CIOCIOLA A: GR 38032F (ondansetron), a selective 5-HT3 receptor an-tagonist, slows colonic transit in healthy man. Dig. Dis. Sci. (1990) 35:477–480.
   PubMed Web of Science ®Google Scholar
• STACHER G, ABATZI WENZEL TA, WIESNAGROTZKI S, BERGMANN H, SCHNEIDER C, GAUPMANN G: Gastric emptying, body weight and symptoms in primary ano-rexia nervosa. Long-term effects of cisapride. Br. J. Psychiatry (1993) 162:398–402.
   PubMed Web of Science ®Google Scholar
• GELDOF H, HAZELHOFF B, OTTEN MH: Two differentdose regimens of cisapride in the treatment of reftux oesophagitis: a double-blind comparison with ranitid-inc. Aliment Pharmacol. Ther (1993) 7:409–415.
   PubMed Web of Science ®Google Scholar
• CORINALDESI R, STANGHELLINI V, TOSETTI C, REA E, CORBELLI C, MARENGO M, MONETTI N, BARBARA L: The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur.J. Clin Pharmacol. (1993) 44:429–432.
   PubMed Web of Science ®Google Scholar
• KAWAGISIII T, NISHIZAWA Y, OKUNO Y, SEKIYA K, MOREH: Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy. Am J. Gastroenterol. (1993) 88:933–938.
   PubMed Web of Science ®Google Scholar
• ALHAIDER AA, LEI SZ, WILCOX GL: Spinal 5-HT3 receptormediated antinodception: Possible release of (MBA. Neurosci. (1991) 11:1881–1888.
   PubMed Web of Science ®Google Scholar
• RICHARDSON BP, ENGEL G, DONATSCH P, STADLER PA:Identification of serotonin M receptor subtypes and their specific blockade by a new class of drugs. Nature (1985) 316:126–131.
   PubMed Web of Science ®Google Scholar
• JAHNEL U, RUPP J, ERTL R, NAWRATH H: Positive inot-ropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol. (1992) 346:482–485.
   PubMed Web of Science ®Google Scholar
• SCHOEMAKER RG, DU XY, BAX WA, SAXENA PR: 5-Hy-droxytryptamine stimulates human isolated atrium but not ventricle. Eur.J. Pharmacol. (1993) 230:103–105.
   PubMed Web of Science ®Google Scholar